Menu Search
Equities

Fennec Pharmaceuticals Inc

RV41:FRA

Fennec Pharmaceuticals Inc

Actions
  • Price (EUR)3.92
  • Today's Change-0.62 / -13.66%
  • Shares traded122.00
  • 1 Year change-47.38%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, cash reserves at Fennec Pharmaceuticals Inc fell by 10.51m. Cash Flow from Financing totalled 6.64m or 31.23% of revenues. In addition the company used 17.14m for operations while cash used for investing totalled .
Cash flow per share0.0979
Price/Cash flow per share42.92
Book value per share-0.0497
Tangible book value per share-0.0497
More ▼

Balance sheet in USDView more

Fennec Pharmaceuticals Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load outweighs its assets while day-to-day operations are losing money. One plus is that there are enough liquid assets to satisfy current obligations, however, this situation is unsustainable over the long run. Fennec Pharmaceuticals Inc has considerable financial risk.
Current ratio8.02
Quick ratio7.75
Total debt/total equity--
Total debt/total capital1.05
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.